Approval · Notice of Compliance 30756 · 2023
SKYRIZI: Notice of Compliance 30756
Issued May 15, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30756
- Date
- May 15, 2023
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product Monograph Update
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SKYRIZI | Not yet assigned | — |
Medicinal ingredients
- RISANKIZUMAB 90 MG per ML
- RISANKIZUMAB 150 MG per ML
- RISANKIZUMAB 360 MG per 2.4ML
- RISANKIZUMAB 60 MG per ML
- RISANKIZUMAB 150 MG per PEN